Game-changer for prostate cancer: Veracyte’s test predicts who will benefit from chemo
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, has announced compelling new data from the phase 3 STAMPEDE clinical trial demonstrating that its Decipher Prostate Genomic Classifier predicts chemotherapy benefit in patients with metastatic prostate cancer. The findings, presented at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, support Veracyte’s plan […]